FDA Letter API

Drive DeVilbiss Healthcare LLC

Letter data

Company
Drive DeVilbiss Healthcare LLC
Recipient
Derek Lampert | Chief Executive Officer (CEO) | Drive DeVilbiss Healthcare LLC | 99 Seaview Blvd, Suite 210 | Port Washington | , | NY | 11050 | United States
Issue date
2024-10-23
Posted date
Not available
FDA office
Office of Medical Device and Radiological Health Operations (Division 1)
Subject
Not available
Product
Medical Devices
CMS ID
619182
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Drive DeVilbiss Healthcare LLC MARCS-CMS 619182 — October 23, 2024 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Medical Devices Recipient: Recipient Name Derek Lampert Recipient Title Chief Executive Officer (CEO) Drive DeVilbiss Healthcare LLC 99 Seaview Blvd, Suite 210 Port Washington , NY 11050 United States Issuing Office: Office of Medical Device and Radiological Health Operations (Division 1) United States Secondary Issuing Offices United States Dear Mr. Lampert: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS # 619182, dated November 23, 2021. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ RDML Sean M. Boyd, MPH, USPHS Director Office of Regulatory Programs Office of Product Evaluation and Quality Center for Devices and Radiological Health Content current as of: 10/30/2024 Regulated Product(s) Medical Devices